APOA1 and cardiovascular disorder: This methodology can now be employed to explore subtle changes in ApoA-I levels as a potential biomarker of cardiovascular disease and as a biological response indicator for tobacco smoking to complement the use of urinary nicotine metabolites [112], NNAL [113], isoprostanes [114], and 8-oxo-dGuo [115].